98 related articles for article (PubMed ID: 9108670)
1. Theodore R. Woodward Award. Age-related decline in growth hormone secretion: clinical significance and potential reversibility.
Thorner MO
Trans Am Clin Climatol Assoc; 1997; 108():99-105; discussion 105-8. PubMed ID: 9108670
[TBL] [Abstract][Full Text] [Related]
2. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
3. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
[TBL] [Abstract][Full Text] [Related]
4. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
7. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
9. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
11. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.
Juul A; Holm K; Kastrup KW; Pedersen SA; Michaelsen KF; Scheike T; Rasmussen S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1997 Aug; 82(8):2497-502. PubMed ID: 9253324
[TBL] [Abstract][Full Text] [Related]
12. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
13. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
14. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
[TBL] [Abstract][Full Text] [Related]
15. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
16. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor axis and plasma lipid levels in the elderly.
Ceda GP; Dall'Aglio E; Magnacavallo A; Vargas N; Fontana V; Maggio M; Valenti G; Lee PD; Hintz RL; Hoffman AR
J Clin Endocrinol Metab; 1998 Feb; 83(2):499-502. PubMed ID: 9467564
[TBL] [Abstract][Full Text] [Related]
18. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation.
Walenkamp MJ; Vidarsdottir S; Pereira AM; Karperien M; van Doorn J; van Duyvenvoorde HA; Breuning MH; Roelfsema F; Kruithof MF; van Dissel J; Janssen R; Wit JM; Romijn JA
Eur J Endocrinol; 2007 Feb; 156(2):155-65. PubMed ID: 17287404
[TBL] [Abstract][Full Text] [Related]
20. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.
Khorram O; Yeung M; Vu L; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3590-6. PubMed ID: 9360512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
